Form 8-K - Current report:
SEC Accession No. 0001104659-24-124597
Filing Date
2024-12-02
Accepted
2024-12-02 16:27:12
Documents
19
Period of Report
2024-11-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2429720d1_8k.htm   iXBRL 8-K 48233
2 EXHIBIT 4.1 tm2429720d1_ex4-1.htm EX-4.1 91084
3 EXHIBIT 4.2 tm2429720d1_ex4-2.htm EX-4.2 120656
4 EXHIBIT 4.3 tm2429720d1_ex4-3.htm EX-4.3 105529
5 EXHIBIT 10.1 tm2429720d1_ex10-1.htm EX-10.1 258132
6 EXHIBIT 10.2 tm2429720d1_ex10-2.htm EX-10.2 136783
7 EXHIBIT 99.1 tm2429720d1_ex99-1.htm EX-99.1 9211
  Complete submission text file 0001104659-24-124597.txt   1133319

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA rnaz-20241126.xsd EX-101.SCH 3054
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE rnaz-20241126_lab.xml EX-101.LAB 34240
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rnaz-20241126_pre.xml EX-101.PRE 22385
21 EXTRACTED XBRL INSTANCE DOCUMENT tm2429720d1_8k_htm.xml XML 3795
Mailing Address 6 LIBERTY SQUARE #2382 BOSTON MA 02109
Business Address 6 LIBERTY SQUARE #2382 BOSTON MA 02109 857-301-6857
Transcode Therapeutics, Inc. (Filer) CIK: 0001829635 (see all company filings)

EIN.: 811065054 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40363 | Film No.: 241519412
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)